How valid are animal models to evaluate treatments for pulmonary hypertension?
Various animal models of pulmonary hypertension (PH) exist, among which injection of monocrotaline (MCT) and exposure to hypoxia are used most frequently. These animal models have not only been used to characterize the pathophysiology of PH and its sequelae such as right ventricular hypertrophy and failure, but also to test novel therapeutic strategies. This manuscript summarizes the available treatment studies in animal models of PH, and compares the findings to those obtained in patients with PH. The analysis shows that all approaches which have proven successful in patients, most notably prostacyclin and its analogs and endothelin receptor antagonists, are also effective in various animal models. However, the opposite it not always true. Therefore, promising results in animals have to be interpreted carefully until confirmed in clinical studies.
Campian
Maria E
ME
Department of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Hardziyenka
Maxim
M
Michel
Martin C
MC
Tan
Hanno L
HL
D000818:Animals; D030801:Animals, Genetically Modified; D004195:Disease Models, Animal; D004373:Ductus Arteriosus / Q000502:physiology; D004617:Embolism / Q000150:complications / Q000503:physiopathology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D000860:Hypoxia / Q000503:physiopathology; D016686:Monocrotaline; D011042:Poisons
D011042:Poisons; D016686:Monocrotaline